If SRSF2 is confirmed to be a key player in mediating the 4R isoform upregulation in PSP and other 4R tauopathies, this would make it a suitable drug target for reducing this isoform shift. This evidence concerns the gene SRSF2 and supranuclear palsy, progressive, 1.